Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127700431 | 12770043 | 1 | I | 20160630 | 20160908 | 20160922 | 20160922 | EXP | GB-LUPIN PHARMACEUTICALS INC.-E2B_00006166 | LUPIN | 44.00 | YR | M | Y | 0.00000 | 20160922 | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127700431 | 12770043 | 1 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | U | UNKNOWN | 0 | |||||||||
127700431 | 12770043 | 2 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | U | UNKNOWN | 0 | 300 | MG | /month | ||||||
127700431 | 12770043 | 3 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | U | UNKNOWN | 0 | 500 | MG | /month | ||||||
127700431 | 12770043 | 4 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | U | UNKNOWN | 78103 | 40 | MG | |||||||
127700431 | 12770043 | 5 | C | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
127700431 | 12770043 | 6 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
127700431 | 12770043 | 7 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 0 | 30 | MG | QD | ||||||||
127700431 | 12770043 | 8 | C | Procyclidine | PROCYCLIDINE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
127700431 | 12770043 | 9 | C | Sodium valproate | VALPROATE SODIUM | 1 | Oral | 0 | 200 | MG | QD | ||||||||
127700431 | 12770043 | 10 | C | THIAMINE. | THIAMINE | 1 | Oral | 0 | 100 | MG | QD | ||||||||
127700431 | 12770043 | 11 | C | Zopiclone | ZOPICLONE | 1 | Oral | 0 | 3.75 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127700431 | 12770043 | 1 | Schizophrenia |
127700431 | 12770043 | 2 | Schizophrenia |
127700431 | 12770043 | 4 | Product used for unknown indication |
127700431 | 12770043 | 5 | Product used for unknown indication |
127700431 | 12770043 | 6 | Product used for unknown indication |
127700431 | 12770043 | 7 | Product used for unknown indication |
127700431 | 12770043 | 8 | Product used for unknown indication |
127700431 | 12770043 | 9 | Product used for unknown indication |
127700431 | 12770043 | 10 | Product used for unknown indication |
127700431 | 12770043 | 11 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127700431 | 12770043 | HO |
127700431 | 12770043 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127700431 | 12770043 | Blood creatine phosphokinase increased | |
127700431 | 12770043 | Psychotic disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127700431 | 12770043 | 1 | 20100513 | 20160625 | 0 |